Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Pulmonology
•
Asthma
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Related Questions
For how long do you recommend treatment for latent tuberculosis prior to initiation of anti-TNF therapy?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
Do you combine methotrexate and leflunomide for the treatment of RA?
How do you approach initiation/continuation of biologics if there is a suspicious pulmonary nodule that requires close interval imaging (i.e every 3 or 6 months)?
What is your approach to the evaluation of a patient with persistent costochondritis?
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
What are best practices in management of severe acute infusion reaction from infliximab?
How do you manage a patient with severe RA or SLE that worsens after stopping immunosuppressants due to having chronic foot ulceration?
How do you approach management of adult patients with CVID and sarcoid-like syndrome?
